$5.75
+1.95%
2026-09-04 12:21:26 EDT+$0.11
헬스케어
생명공학
NASDAQ
활발히 거래 중
Seres Therapeutics, Inc.는 숙주 세포와 조직을 조절하여 다양한 질병에 대응하도록 세균 컨소시엄을 공학적으로 설계하는 데 전념하는 선도적인 마이크로바이옴 치료 기업입니다. 이들의 대표 ...
Seres Therapeutics, Inc.는 숙주 세포와 조직을 조절하여 다양한 질병에 대응하도록 세균 컨소시엄을 공학적으로 설계하는 데 전념하는 선도적인 마이크로바이옴 치료 기업입니다. 이들의 대표 ...
C-레벨 임원은 회사의 재무 전략과 혁신을 이끄는 응집된 리더십 팀입니다.
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| Thomas J. DesRosier | 부사장(Executive VP), 최고 법무책임자(Chief Legal Officer) 및 비서(Secretary) | USD 689,733 | 1955 | Active | |
| Marella Thorell | 부사장(Executive VP), 최고재무책임자(CFO) 및 재무담당(Treasurer) | USD 667,106 | 1967 | Active | |
| Matthew R. Henn | 사장(President) 및 최고 과학책임자(Chief Scientific Officer) | USD 492,375 | — | 1975 | Active |
| Chris McChalicher | 부회장(Executive Vice President) 및 최고기술책임자(Chief Technology Officer) | USD 142,708 | — | Active | |
| Richard N. Kender | 임시 CEO 및 이사회 의장(Executive Chair) | USD 72,500 | 1956 | Active | |
| Dennis Walling | 임상개발 수석 부사장(Senior Vice President) 및 임상연구 책임자(Head of Clinical Research) | — | — | — | Active |
| Ann Kurowski | 규제업무 수석 부사장(Senior Vice President) | — | — | Active | |
| Kelly Brady | 부사장(Executive VP) 및 COO | — | 1984 | Active |
| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 2025 | Eric D. Shaff | Former Former President President and Chief Chief Executive Officer | Founder / CEO | $408.33K | $0 | $0 | $1.34M | $0 | $28.35K | $1.78M |
| 2026-04-27 | 2025 | Thomas J. DesRosier | Former Former Co-President and Co-Chief Executive Officer and current Executive Vice Vice President President and Chief Chief Legal Officer | Founder / CEO | $512.90K | $166.67K | $0 | $446.29K | $0 | $10.17K | $1.14M |
| 2026-04-27 | 2025 | Marella Thorell | Former Former Co-President and Co-Chief Executive Officer and current Executive Vice Vice President President and Chief Chief Financial Officer | Founder / CEO | $494.40K | $166.67K | $0 | $446.29K | $0 | $6.04K | $1.11M |
| 2026-04-27 | 2025 | Teresa L. Young, Ph.D. | Former Former Executive Vice Vice President President and Chief Chief Commercial and Strategy Officer | C-Level | $489.30K | $0 | $75.68K | $446.29K | $0 | $10.19K | $1.02M |
| 2026-04-27 | 2025 | Matthew Henn, Ph.D. | President President and Chief Chief Scientific Officer | C-Level | $489.30K | $0 | $75.68K | $446.29K | $0 | $3.08K | $1.01M |
| 2026-04-27 | 2024 | Eric D. Shaff | Former Former President President and Chief Chief Executive Officer | Founder / CEO | $685.00K | $0 | $116.88K | $1.46M | $411.00K | $9.30K | $2.68M |
| 2026-04-27 | 2024 | Thomas J. DesRosier | Former Former Co-President and Co-Chief Executive Officer and current Executive Vice Vice President President and Chief Chief Legal Officer | Founder / CEO | $498.00K | $0 | $39.19K | $502.18K | $199.20K | $9.94K | $1.25M |
Sum of disclosed compensation by year (USD million)
Top founder/C-level executives over time (USD million)